Arcutis Biotherapeutics Inc

ARQT is in a Lockout Rally continuation, with price extended above rising EMAs and supported by elevated volume. The Stage 2 medium-term structure remains bullish, reinforced by the continuation pattern. Short-term timing is favorable under the Lockout Rally override despite extreme overbought readings, enabling immediate participation above prior highs.

• ↑Q1 net product revenue soared 65% YoY to $105.4M on Zareve demand
• ↑Supplemental NDA for Zareve Cream 0.05% targets ~2–2.5M infants
• ↓Low earnings yield and weak profitability factors raise valuation concerns